Study Seeking Those with Relapsing Neuromyelitis Optica (NMO)

Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial To Evaluate The Safety And Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)

Purpose:

The purpose of this study is to assess the efficacy, safety and tolerability of eculizumab treatment as compared with placebo in those with Relapsing Neuromyelitis Optica (NMO).

Eligibility criteria:

- Diagnosis of Neuromyelitis Optica (NMO)
- NMO-IgG seropositive either historical or at screening
- Historical Relapse of at least 2 relapses in the last 12 months or 3 relapses in the last 24 months, with at least 1 relapse in the 12 months

* Please contact study coordinator for more detailed inclusion/exclusion criteria

Contact Information


Stephanie Scarsberry
614-688-4678
stephanie.scarberry@osumc.edu

Back